An observational study in Systemic Autoimmune Disease, Chronic Inflammatory Rheumatism and Sjogren's Syndrome, sponsored by Assistance Publique - Hôpitaux de Paris. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-11.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Exploration of pathophysiological mechanisms in chronic inflammatory rheumatism and rare systemic autoimmune diseases with the objective of identifying therapeutic targets.
The primary objective is to characterization of the quantitative and qualitative specificities of the different leukocyte sub-populations in patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases. We will perform an exploratory descriptive study whom primary endpoint will be to assess by FACS the phenotype of the specific leukocyte subsets. In addition, we will characterize the protein and transcriptomic signature associated with the conditions for which we have obtained preliminary data showing their potential involvement in autoimmunity (i.e: IL7 pathway, IFN signature).
381 studies on the registry are indexed under Sjogren's Syndrome; 106 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 114 across 115 observational studies indexed under Sjogren's Syndrome.
Browse Sjogren's Syndrome studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,576 studies on the registry; 1,028 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
sampling of blood for research during routine care
Characterization of the quantitative and qualitative specificities of the different leukocyte subpopulations in patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases
Proportion of different leukocytes subset
Time frame: At the end of the study (5 years)
Protein study (ELISA on serum) : IL7
levels of IL7 and other cytokines
Time frame: At the end of the study (5 years)
Transcriptome study (RNA) : mRNA levels
assessement of different mRRNA involved in Il7/IFN pathways by molecular biology techniques (RNAseq, qPCR, nano string)
Time frame: At the end of the study (5 years)
Genomic study (DNA) : SNPs
Determination of the genotype of different SNPs involved in IL7/IFN pathways
Time frame: At the end of the study (5 years)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2021; primary completion for Mar 2026, 60 months later.
Of 48 non-industry observational studies under Sjogren's Syndrome, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 124. This study's planned 60 months is close to that.
Counting every sponsor, half of 50 studies reached it within 64 months; a quarter within 21 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →